Insider Selling: Twist Bioscience Co. (NASDAQ:TWST) SVP Sells 1,347 Shares of Stock

Twist Bioscience Co. (NASDAQ:TWST) SVP Paula Green sold 1,347 shares of the business’s stock in a transaction dated Monday, November 11th. The shares were sold at an average price of $48.00, for a total value of $64,656.00. Following the completion of the sale, the senior vice president now directly owns 114,147 shares of the company’s stock, valued at approximately $5,479,056. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Paula Green also recently made the following trade(s):

• On Wednesday, November 6th, Paula Green sold 5,519 shares of Twist Bioscience stock. The stock was sold at an average price of $44.60, for a total value of $246,147.40.
• On Monday, November 4th, Paula Green sold 1,057 shares of Twist Bioscience stock. The shares were sold at an average price of $41.56, for a total value of $43,928.92.
• On Wednesday, October 2nd, Paula Green sold 3,310 shares of Twist Bioscience stock. The stock was sold at an average price of $43.21, for a total value of $143,025.10.
• On Friday, September 20th, Paula Green sold 297 shares of Twist Bioscience stock. The shares were sold at an average price of $46.94, for a total transaction of $13,941.18.

Twist Bioscience Stock Down 6.1 %

TWST traded down $2.77 during trading hours on Wednesday, hitting $42.49. The company’s stock had a trading volume of 962,106 shares, compared to its average volume of 941,048. Twist Bioscience Co. has a fifty-two week low of $18.59 and a fifty-two week high of $60.90. The company has a 50-day simple moving average of $43.86 and a 200 day simple moving average of $45.95.

Institutional Investors Weigh In On Twist Bioscience

Hedge funds and other institutional investors have recently modified their holdings of the stock. American International Group Inc. raised its position in shares of Twist Bioscience by 0.8% during the 1st quarter. American International Group Inc. now owns 28,506 shares of the company’s stock worth $978,000 after buying an additional 213 shares in the last quarter. Caprock Group LLC raised its holdings in Twist Bioscience by 2.9% during the second quarter. Caprock Group LLC now owns 7,851 shares of the company’s stock worth $387,000 after purchasing an additional 220 shares in the last quarter. Signaturefd LLC raised its holdings in Twist Bioscience by 63.0% during the third quarter. Signaturefd LLC now owns 792 shares of the company’s stock worth $36,000 after purchasing an additional 306 shares in the last quarter. Arizona State Retirement System lifted its position in Twist Bioscience by 1.9% in the second quarter. Arizona State Retirement System now owns 16,187 shares of the company’s stock worth $798,000 after purchasing an additional 308 shares during the period. Finally, Massachusetts Financial Services Co. MA boosted its stake in Twist Bioscience by 3.5% during the 2nd quarter. Massachusetts Financial Services Co. MA now owns 9,279 shares of the company’s stock valued at $457,000 after purchasing an additional 312 shares in the last quarter.

Analysts Set New Price Targets

Several research firms have recently commented on TWST. Barclays decreased their price target on shares of Twist Bioscience from $60.00 to $55.00 and set an “overweight” rating for the company in a report on Monday, August 5th. Evercore ISI lifted their target price on Twist Bioscience from $52.00 to $56.00 and gave the company an “outperform” rating in a research note on Tuesday, October 1st. Leerink Partners upped their target price on Twist Bioscience from $45.00 to $48.00 and gave the company a “market perform” rating in a report on Thursday, October 17th. Robert W. Baird raised their price target on Twist Bioscience from $40.00 to $46.00 and gave the stock an “outperform” rating in a report on Monday, August 5th. Finally, JPMorgan Chase & Co. upped their price objective on Twist Bioscience from $28.00 to $35.00 and gave the stock an “underweight” rating in a research note on Monday, August 5th. One analyst has rated the stock with a sell rating, one has issued a hold rating and seven have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $51.22.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.